Last March, Orexigen ($OREX) landed in hot water with researchers, the FDA and marketing partner Takeda when it blabbed some early trial results that falsely suggested its obesity med could improve cardiovascular outcomes for patients. Just over a year later, it's still facing the consequences. Former FDA deputy commissioner Joshua Sharfstein is calling for U.S. regulators to propose restrictions on the drug, Contrave, to counter the "misleading information" from the California company, Forbes reports. And the FDA has some tools to do that, he noted, including a Risk Evaluation and Mitigation Strategy. More from FiercePharma